Please ensure Javascript is enabled for purposes of website accessibility

The End of the Pandemic Will Mean a Major Boost for These 2 Buy-and-Hold Stalwarts

By Alex Carchidi - May 4, 2021 at 6:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

People will be getting back to their regular routines when it comes to medical and dental care.

It's no secret that in-person medical appointments are hard to come by in the age of COVID-19. But now that the U.S. appears to be getting the pandemic under control, people are eagerly flocking back to the clinic for everything they've put off, from dental cleanings to heart surgery. 

Okay, perhaps some aren't exactly thrilled to be catching up on their deferred healthcare, but the ongoing influx of business is certainly going to drive the next few quarters of earnings across the industry. And, luckily for investors, there is a pair of reliable and rapidly growing medical device companies that are poised to benefit in a big way. Though neither of the two stocks are cheap at their present valuations, both could soar higher as life gets back on track, and that makes them worth a closer look.

Young female healthcare worker wearing scrubs stands in front of desktop computers at work.

Image source: Getty Images

1. Align Technologies

When the pandemic hit, cosmetic dentistry ground to a halt, and that gave Align Technologies (ALGN 1.44%) a rough start to 2020. The company makes the Invisalign brand of transparent tooth straighteners, each of which is individually shaped to fit for all of its nine million patients by an army of nearly 190,000 expert orthodontists.

In the second quarter of 2020, it moved only 221,900 cases of its straighteners, compared to 359,400 cases in the prior three months. While its business quickly recovered and ended the year on a high note of 568,000 cases sold in the final quarter, there's no way around the fact that patients need to attend in-person consultations with their doctor before starting to use teeth aligners. 

Worldwide, Align only grew its volume of shipments by 13.3% in 2020. That's a sharp drop from its growth of 34% in 2019 and 45% in 2018. So, as more and more people get vaccinated and start to be more willing to initiate consultations to start their tooth straightening treatment, it's highly likely that sales growth will return to the steep upward trajectory that it was on before the pandemic.

That's especially probable given the company's new advertising and consumer outreach campaigns in its high-growth markets like Germany. For investors seeking a reliable growth stock that's approaching its prime, it's hard to go wrong with Align.

^SPX Chart

^SPX data by YCharts

2. Abiomed

As a result of chaos in the second quarter of last year, heart pump manufacturer Abiomed (ABMD -1.29%) took a major performance hit, with its total revenue growing by only 9%, reaching $841 million. With people staying at home and deferring nonessential activities, there aren't as many opportunities for them to get into the kind of medical trouble that might require mechanical support for their heart.

Now that nonessential surgeries are resuming and hospital capacity is no longer scarce, the company is ready to return to its prior rate of growth. From 2017 to 2019, its total revenues grew between 30% and 35% each year -- and in the near future, that could accelerate for two key reasons. 

The first reason is that in June 2020, Abiomed's Impella pumps received emergency approval to be used in patients who are experiencing heart failure as a result of COVID-19 infections. Given that the virus can cause heart issues in many people, the newly approved indication is an entirely new market for the company's products, though it remains to be seen how large the opportunity will be in the long term. 

The second reason that investors should be bullish about Abiomed's future is that management has been diligent in continuing to invest in future opportunities during the doldrums of the pandemic. The company recently initiated a new clinical trial investigating whether its Impella heart pump is suitable for use in high-risk percutaneous coronary interventions, a class of heart surgeries.

The trial builds on previous studies of the Impella that showed a 29% reduction in adverse outcomes like death, heart attacks, and strokes in the 90 days after being treated. If it is successful in the ongoing study, it'll expand the addressable market for its pumps significantly, and revenue growth will be sure to follow. Still, it could be a few years until the trial and the regulatory paperwork are complete, so investors should set their expectations accordingly.

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Abiomed and Align Technology. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Align Technology, Inc. Stock Quote
Align Technology, Inc.
ALGN
$281.66 (1.44%) $4.00
ABIOMED, Inc. Stock Quote
ABIOMED, Inc.
ABMD
$278.18 (-1.29%) $-3.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.